Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer.
The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.
The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -2.16 Decreased by -800.00% | -2.16 |
| Mar 25, 24 | -3.42 Decreased by -1.45 K% | -1.65 Decreased by -107.27% |
| Nov 13, 23 | -0.13 Increased by +43.48% | -0.12 Decreased by -8.33% |
| Aug 8, 23 | -0.17 Increased by 0.00% | -0.20 Increased by +15.00% |
| May 9, 23 | -0.24 Decreased by -442.86% | -0.14 Decreased by -71.43% |
| Mar 8, 23 | -0.22 Decreased by -150.00% | -0.24 Increased by +8.33% |
| Nov 7, 22 | -0.23 Decreased by -154.76% | -0.21 Decreased by -9.52% |
| Aug 9, 22 | -0.17 Increased by +54.05% | -0.16 Decreased by -6.25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -8.83 M Increased by +11.78% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 162.00 K Decreased by -76.00% | -9.13 M Increased by +1.41% | Decreased by -5.64 K% Decreased by -310.77% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -8.30 M Increased by +13.14% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -8.36 M Decreased by -20.95% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -10.01 M Decreased by -426.30% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 675.00 K Decreased by -52.80% | -9.26 M Decreased by -148.61% | Decreased by -1.37 K% Decreased by -202.98% |
| Sep 30, 22 | 867.00 K Increased by +103.04% | -9.56 M Decreased by -207.66% | Decreased by -1.10 K% Decreased by -153.02% |
| Jun 30, 22 | 2.01 M Increased by +N/A% | -6.92 M Decreased by -24.64% | Decreased by -343.86% Decreased by N/A% |